Updated Oct. 1, 2012 at 7:53 a.m.

Premium Lock Study: GSK drug as effective as Pfizer's for kidney cancer

Published: 2012-10-01 06:38:00
Updated: 2012-10-01 07:53:28

Print this blog post
Cancer research Cancer research Image 1 of 2 · Next Image…

For both drugs, the average progression-free survival was slightly more than 10 months, according to a GSK-funded study of 1,100 patients that was announced Monday....

Read More
Read More

WRAL Tech Wire any time: Twitter, Facebook

Copyright 2014 Bloomberg. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL Tech Wire and WRAL editors. Read more articles…

Please Log In to add a comment.

Best of TechWire Insider

Techwire Inside Partners


Frank Vinluan
Life science
Vivek Wadhwa
Dr. Mike Walden
Tech economy